

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4758953

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
REPLIGEN CORPORATION	03/12/2014
RECEIVING PARTY DATA	
Name:	BIOMARIN PHARMACEUTICAL INC.
Street Address:	105 DIGITAL DRIVE
City:	NOVATO
State/Country:	CALIFORNIA
Postal Code:	94949
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15860741
CORRESPONDENCE DATA	
Fax Number:	(312)474-0448
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3124746300
Email:	docket@marshallip.com
Correspondent Name:	WALESKA SALGADO
Address Line 1:	233 SOUTH WACKER DRIVE
Address Line 2:	SUITE 6300
Address Line 4:	CHICAGO, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	30610/40059C3 US
NAME OF SUBMITTER:	SHELLEY DANEK
SIGNATURE:	/Shelley Danek/
DATE SIGNED:	01/03/2018
Total Attachments: 3	
source=Executed_Assignment_Repligen_To_BioMarin#page1.tif	
source=Executed_Assignment_Repligen_To_BioMarin#page2.tif	
source=Executed_Assignment_Repligen_To_BioMarin#page3.tif	

Assignment Agreement

This assignment agreement ("Assignment") is entered into between Repligen Corporation ("Assignor"), having a place of business at 41 Seyon Street, Building #1, Suite 100, Waltham, Massachusetts, and BioMarin Pharmaceutical Inc. ("Assignee"), a corporation incorporated in the state of Delaware, having its principal place of business at 105 Digital Drive, Novato, CA 94949 ("Assignee"). This Assignment is effective as of January 21, 2014.

For good and valuable consideration previously received, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign and transfer unto Assignee all of its right, title and interest in and to the patents and patent applications listed in Exhibit A hereto (collectively "Patents"), the inventions described in the Patents, and any U.S. or foreign applications or patents based or granted on said inventions, or any parts thereof, and any U.S. or foreign applications, or patents claiming priority based on the Patents, including continuations, continuations in part, divisions, reexaminations, reissues, inter partes reexaminations, post grant reviews, substitutes, renewals or extensions of any of the foregoing, including all rights of priority under the International Convention for the Protection of Industrial Property, and all rights to sue for damages and other remedies in respect of any infringement of such U.S. or foreign applications or patents or other acts within the scope of the claims of any published specifications of such U.S. or foreign applications.

The undersigned signing on behalf of Repligen Corporation warrants s/he is authorized to execute this document on behalf of Repligen Corporation.

IN WITNESS WHEREOF, the parties hereto have executed and delivered this Assignment.

On behalf of Repligen Corporation:

Signature: _____

Name: _____

Title: _____

Date: _____

WITNESSES:

Signature: _____

Name: _____

Signature: _____

Name: _____

ACKNOWLEDGEMENT BY ASSIGNEE

BioMarin Pharmaceutical Inc. hereby acknowledges receipt of this assignment, for good and valuable consideration, of Patent Rights listed in Schedule A.

BioMarin Pharmaceutical Inc.

By: Jim Bigorna

Name: Luisa Bigorna

Title: VP, Intellectual Property

Schedule A

WO (Family) Number	F&R #	STATUS	APPLN #	FILED	PATENT #	ISSUED	TITLE
WO2009055675 (Methods of Identifying)	00231-0124AU1	PENDING	2008316667	24-Oct-08			METHODS OF IDENTIFYING HISTONE DEACETYLASE INHIBITORS USEFUL FOR
	00231-0124CA1	PENDING	2703742	24-Oct-08			METHODS OF IDENTIFYING HISTONE DEACETYLASE INHIBITORS USEFUL FOR
	00231-0124DE1	ISSUED	08841518.7	24-Oct-08	602008016577.9	20-Jun-12	METHODS OF IDENTIFYING HISTONE DEACETYLASE INHIBITORS USEFUL FOR
	00231-0124FR1	ISSUED	08841518.7	24-Oct-08	2214483	20-Jun-12	METHODS OF IDENTIFYING HISTONE DEACETYLASE INHIBITORS USEFUL FOR
	00231-0124GB1	ISSUED	08841518.7	24-Oct-08	2214483	20-Jun-12	METHODS OF IDENTIFYING HISTONE DEACETYLASE INHIBITORS USEFUL FOR
WO2010028192 (RG2833)	00231-0127AU1	PENDING	2009289649	03-Sep-09			COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS
	00231-0127CA1	PENDING	2735593	03-Sep-09			COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS
	00231-0127EP1	PUBLISHED	09812248.4	03-Sep-09			COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS
	00231-0127US1	PUBLISHED	13/062,030	12-Dec-11			COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS
	00231-0143AU1	PENDING	N/A	28-Feb-12			HISTONE DEACETYLASE INHIBITORS
WO2012118782 (RG3250)	00231-0143CA1	PENDING	N/A	28-Feb-12			HISTONE DEACETYLASE INHIBITORS
	00231-0143EP1	PENDING	N/A	28-Feb-12			HISTONE DEACETYLASE INHIBITORS
	00231-0143JP1	PENDING	N/A	28-Feb-12			HISTONE DEACETYLASE INHIBITORS
	00231-0143US1	PENDING	13/823,708	14-Mar-13			HISTONE DEACETYLASE INHIBITORS
	00231-0153001	PENDING	13/843,261	15-Mar-13			HISTONE DEACETYLASE INHIBITORS
March/Aug Provisionals (1087/1088)	9023-0152P01	PENDING	61/800,170	15-Mar-13			HDAC INHIBITORS
	00231-0152P02	PENDING	61/863,235	07-Aug-13			HDAC INHIBITORS